



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1495-TO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: March 18, 2010 (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/576,794
Sheet 1		of 6		Filing Date	05/24/2007
				First Named Inventor	Abdessatar Chtourou
				Art Unit	1656
				Examiner Name	Marsha M. Tsay
				Attorney Docket Number	096183-0103

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document Serial Number-Kind Code <sup>2</sup> (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A1	EP 1 270 595 B1	01/02/2003	Kyowa Hakko Kogyo Co., Ltd.		
	A2	EP 1 443 961 B1	08/11/2004	Genentech, Inc.		
	A3	EP 1 331 266 A1	07/30/2003	Kyowa Hakko Kogyo Co., Ltd.		

NON PATENT LITERATURE DOCUMENTS					T <sup>6</sup>
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	A4	Advanced Catalogue Search, ATCC Number CRL-1662, Product Description, [online] [retrieved on Sept. 22, 2009]. Retrieved from the Internet: <URL: mhtml:file://W:\Intellectual Property\APPLICATIONS\OPPOSITIONS\LFB\atcc crl ...>.			
	A5	Advanced Catalogue Search, ATCC Number CRL-1823, Product Description [online] [retrieved on 09/22/2009]. Retrieved from the Internet: <URL: http://www.lgcstandards-atcc.org/LGCAdvancedCatalogueSearch/Product Description...>.			
	A6	ALBERTS, et al., "Molecular Biology of The Cell, 3 <sup>rd</sup> Ed., p. 1206, Ch. 23: <i>The Immune System</i> , Garland Publishing.			
	A7	ARMSTRONG-FISHER et al., "Evaluation of a panel of human monoclonal antibodies to D and Exploration of the synergistic effects of blending IgG1 and IgG3 antibodies on their in vitro biologic function," <i>Transfusion</i> , Aug. 1999, pp. 1005-1012, Vol. 39.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: March 18, 2010 (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/576,794
				Filing Date	05/24/2007
				First Named Inventor	Abdessatar Chtourou
				Art Unit	1656
				Examiner Name	Marsha M. Tsay
Sheet	2	of	6	Attorney Docket Number	096183-0103

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A8	Blood Plasma, Wikipedia, [online] [retrieved on 09/22/2009]. Retrieved from the Internet: <URL: <a href="http://en.wikipedia.org/wiki/Blood_plasma">http://en.wikipedia.org/wiki/Blood_plasma</a> >, 3 pages. Revision history of Blood plasma, Wikipedia, [online] [retrieved 09/22/2009]. Retrieved from the Internet: <URL: <a href="http://en.wikipedia.org/w/index.php?title=Blood_plasma&amp;limit=500&amp;action=history">http://en.wikipedia.org/w/index.php?title=Blood_plasma&amp;limit=500&amp;action=history</a> >, 18 pages.			
	A9	BOYD et al., "The Effect of the Removal of Sialic Acid, Galactose and Total Carbohydrate on the Functional Activity of Campath-1H," <i>Mole. Immunol.</i> , 1995, pp. 1311-1318, Vol. 32, Nos. 17/18.			
	A10	BRAND, A., "Immunosuppression and Immunomodulation," <i>Immunological and Infectious Diseases of the Peripheral Nerves</i> , Latov et al., editors, Cambridge University Press, Chapter 24, pp. 366-368, 1998.			
	A11	BREDIUS et al., "Role of neutrophil FcγRIIa (CD32) and FcγRIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes," <i>Immunology</i> , 1994, pp. 624-630, Vol. 83.			
	A12	CANT et al., "Glycosylation and functional activity of anti-D secreted by two human lymphoblastoid cell lines," <i>Cytotechnology</i> , 1994, pp. 223-228, Vol. 15.			
	A13	CARROLL et al., "Mouse X human heterohybridomas as fusion partners with human," <i>J. Immunol. Methods</i> , 1986, pp. 61-72, Vol. 89, Elsevier.			
	A14	CD61, Wikipedia, [online] [retrieved on 09/22/2009]. Retrieved from the Internet: <URL: <a href="http://en.wikipedia.org/wiki/CD61">http://en.wikipedia.org/wiki/CD61</a> >, 5 pages. Revision history of CD61, [online] [retrieved on 09/22/2009]. Retrieved from the Internet: <URL: <a href="http://en.wikipedia.org/w/index.php?title=CD61&amp;action=history">http://en.wikipedia.org/w/index.php?title=CD61&amp;action=history</a> >, 1 page.			
	A15	CHOWDHURY et al., "Tailor-made antibody therapeutics," <i>Methods</i> , 2005, pp. 11-24, Vol. 36, Elsevier.			
	A16	DUCROT et al., "Use of the DAF Assay to Assess the Functional Properties of Polyclonal and Monoclonal Rh D Antibodies," <i>Vox Sang</i> , 1996, pp. 30-36, Vol. 71.			
	A17	GALILI et al., "A Unique Natural Human IgG Antibody with Anti-α-Galactosyl Specificity," <i>J. Exp. Med.</i> , Nov. 1984, pp. 1519-1531, Vol. 160.			
	A18	GOOSSENS, et al., "Human monoclonal antibodies against blood group antigens. Preparation of a series of stable EBV immortalized B clones producing high levels of antibody of different isotypes and specificities," <i>J. Immunol. Methods</i> , 1987, pp. 193-200, Vol. 101, Elsevier.			
	A19	GREENMAN et al., "Comparative efficiencies of bispecific F(ab'γ) <sub>2</sub> and chimeric mouse/human IgG antibodies in recruiting cellular effectors for cytotoxicity via Fcγ receptors," <i>Cancer Immunol. Immunother.</i> , 1992, pp. 361-369, Vol. 34.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: March 18, 2010 (use as many sheets as necessary)		<b>Complete if Known</b>	
		<b>Application Number</b> <b>Filing Date</b> <b>First Named Inventor</b> <b>Art Unit</b> <b>Examiner Name</b> <b>Attorney Docket Number</b>	10/576,794 05/24/2007 Abdessatar Chtourou 1656 Marsha M. Tsay 096183-0103
Sheet	3	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A20	HADLEY et al., "The functional activity of FcγRII and FcγRIII on subsets of human lymphocytes," <i>Immunology</i> , 1992, pp. 446-451, Vol. 76.	
	A21	HSU et al., "Differential N-Glycan Patterns of Secreted and Intracellular IgG Produced in <i>Trichoplusia ni</i> Cells," <i>J. Biol. Chem.</i> , Apr. 1997, pp. 9062-9070, Vol. 272, No.14.	
	A22	HUGHES-JONES et al., "Nucleotide sequences and three-dimensional modeling of the V <sub>H</sub> and V <sub>L</sub> domains of two human monoclonal antibodies specific for the D antigen of the human Rh-blood-group system," <i>Biochem. J.</i> , 1990, pp. 135-140, Vol. 268.	
	A23	IP et al., "Structural Characterization of the N-Glycans of a Humanized Anti-CD18 Murine Immunoglobulin G," <i>Archives of Biochemistry and Biophysics</i> , Feb. 1991, pp. 387-399, Vol. 208, No. 2.	
	A24	JEFFERIS et al., "IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation," <i>Immunol. Reviews</i> , 1998, pp. 59-76, Vol. 163.	
	A25	KELER et al., "Bispecific antibody-dependent Cellular Cytotoxicity of HER2/ <i>neu</i> -overexpressing Tumor Cells by Fcγ Receptor Type I-expressing Effector Cells," <i>Cancer Research</i> , Sept. 1997, pp. 4008-4014, Vol. 57.	
	A26	KILMARTIN et al., "Rat Monoclonal Antitubulin antibodies Derived by Using a New Nonsecreting Rat Cell Line," <i>J. Cell Biol.</i> , June 1982, pp. 576-582, Vol. 93.	
	A27	KLEIN et al., "Human recombinant anti-Rh(D) monoclonal antibodies: Improvement of biological properties by <i>in vitro</i> class-switch," <i>Human Antibodies</i> , 1997, pp. 17-25, Vol. 8, No. 1.	
	A28	KUMPEL et al., "Activity and Fcγ receptor utilization of IgG anti-D monoclonal antibodies in monocytes chemiluminescence assays and lymphocyte ADCC assays," 4 <sup>th</sup> Workshop on Mabs against human red blood cells and related antigens, PARIS, 19-20 July 2002, page 1.	
	A29	KUMPEL et al., "Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed By-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity," <i>Hum. Antibod. Hybridomas</i> , 1994, pp. 143-151, Vol. 5, Nos. 3 and 4.	
	A30	KUMPEL et al., "Heterogeneity in the ability of IgG1 monoclonal anti-D to promote lymphocyte-mediated red cell lysis," <i>Eur. J. Immunol.</i> , 1989, pp. 2283-2288, Vol. 19.	
	A31	KUMPEL et al., "Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers," <i>Blood</i> , 1995, pp. 1701-1709, Vol. 86, American Society of Hematology.	
	A32	KUMPEL, B.M., "Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers," <i>Vox Sang.</i> , 2007, pp. 99-111, Vol. 93.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: March 18, 2010 (use as many sheets as necessary)		<b>Complete if Known</b>	
		<b>Application Number</b> <b>Filing Date</b> <b>First Named Inventor</b> <b>Art Unit</b> <b>Examiner Name</b> <b>Attorney Docket Number</b>	10/576,794 05/24/2007 Abdessatar Chtourou 1656 Marsha M. Tsay 096183-0103
Sheet	4	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A33	KUMPEL, B.M., "Monoclonal anti-D for prophylaxis of RhD haemolytic disease of the newborn," <i>Transfus. Clin. Biol.</i> , 1997, pp. 351-356, Vol. 4.	
	A34	LIFELY et al., "Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions," <i>Glycobiology</i> , 1995, pp. 813-822, Vol. 5, No. 8.	
	A35	LUND et al., "Control of IgG/Fc Glycosylation: A Comparison of Oligosaccharides from Chimeric Human/Mouse and Mouse Subclass Immunoglobulin Gs," <i>Mole. Immunol.</i> , 1993, pp. 741-748, Vol. 30, No. 8.	
	A36	MELAMED et al., "Requirements for the establishment of heterohybridomas secreting monoclonal human antibody to rhesus (D) blood group antigen," <i>J. Immunol. Methods</i> , 1987, pp. 245-251, Vol. 104, Elsevier.	
	A37	MERRIAM-WEBSTER, Webster's Third New International Dictionary of the English Language Unabridged, 1961, p. 1761.	
	A38	MORI et al., "Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies," <i>Cytotechnology</i> , 2007, pp. 109-114, Vol. 55.	
	A39	NAKAMURA et al., "Chimeric Anti-Ganglioside GM <sub>2</sub> Antibody with Antitumor Activity," <i>Cancer Research</i> , Mar. 1994, pp. 1511-1516, Vol. 54.	
	A40	PAPAC et al., "A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis," 1998, pp. 463-472, Vol. 8, No. 5.	
	A41	PATERSON et al., "Variation in IgG1 heavy chain allotype does not contribute to differences in biological activity of two human anti-Rhesus (D) monoclonal antibodies," <i>Immunotechnology</i> , 1998, pp. 37-47, Vol. 4, Elsevier.	
	A42	PRESTA, Leonard G., "Engineering of therapeutic antibodies to minimize immunogenicity and optimize function," <i>Advanced Drug Delivery Reviews</i> , 2006, pp. 640-656, Vol. 58, Elsevier.	
	A43	PUTHALAKATH et al., "Glycosylation Defect in Lec1 Chinese Hamster Ovary Mutant Is Due to a Point Mutation in N-Acetylglucosaminyltransferase I Gene," <i>J. Biol. Chem.</i> , Nov. 1996, pp. 27818-27822, Vol. 271, No. 44.	
	A44	RAJU et al., "Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics," <i>Glycobiology</i> , 2000, pp. 477-486, Vol. 10, No. 5.	
	A45	REVILLARD, Jean-Pierre, <i>Immunologie</i> , 2d Ed., 1995, various chapters, DeBoeck Université.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: March 18, 2010 (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/576,794
				Filing Date	05/24/2007
				First Named Inventor	Abdessatar Chtourou
				Art Unit	1656
				Examiner Name	Marsha M. Tsay
Sheet	5	of	6	Attorney Docket Number	096183-0103

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A46	ROTHMAN et al., "Antibody-dependent Cytotoxicity Mediated by Natural Killer Cells is Enhanced by Castanospermine-induced Alterations of IgG Glycosylation," <i>Mole. Immunol.</i> , 1989, pp. 1113-1123, Vol. 26, No. 12.			
	A47	SEGAL et al., "The Role of Non-immune IgG in Controlling IgG-Mediated Effector Functions," <i>Mole. Immunol.</i> , 1983, pp. 1177-1189, Vol. 20, No. 11.			
	A48	SHAW et al., "Human Lymphocyte, Monocyte, and Neutrophil Antibody-Dependent Cell-Mediated Cytotoxicity toward Human Erythrocytes," <i>Cell. Immunol.</i> , 1978, pp. 122-133, Vol. 41.			
	A49	SHIELDS et al., "Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity," <i>J. Bio. Chem.</i> , July 2002, pp. 26733-26740, Vol. 277, No. 30.			
	A50	SHINKAWA et al., "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <i>J. Biol. Chem.</i> , Jan. 2003, pp. 3466-3473, Vol. 278, No. 5.			
	A51	SHITARA et al., "A new vector for the high level expression of chimeric antibodies in myeloma cells," <i>J. Immunol. Methods</i> , 1994, pp. 271-278, Vol. 167, Elsevier Science B.V.			
	A52	SIBÉRIL et al., "Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory FcγR functions," <i>Clinical Immunol.</i> , 2006, pp. 170-179, Vol. 118, Elsevier.			
	A53	TAKAHASHI et al., "Comparative Structural Study of the N-Linked Oligosaccharides of Human IgG Normal and Pathological Immunoglobulin G," <i>Biochemistry</i> , 1987, pp. 1137-1144, Vol. 26.			
	A54	TANDAI et al., "Structural Study of the Sugar Moieties of Monoclonal Antibodies Secreted by Human-Mouse Hybridoma," <i>Archives of Biochemistry and Biophysics</i> , Dec. 1991, pp. 339-348, Vol. 291, No. 2.			
	A55	TEILLAUD, Jean-Luc, "Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges," <i>Expert Opin. Biol. Ther.</i> , 2005, pp. S15-S27, Vol. 5, Suppl. 1, Ashley Publications.			
	A56	UMAÑA et al., "Engineered glycoforms of an antineuro-blastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity," <i>Nature Biotechnology</i> , Feb. 1999, pp. 176-180, Vol. 17.			
	A57	URBANIAK et al., "Prediction of the Outcome of Rhesus Haemolytic Disease of the Newborn: Additional Information Using an ADCC Assay," <i>Vox Sang.</i> , 1984, pp. 323-329, Vol. 46.			
	A58	URBANIAK, S.J., "ADCC (K-Cell) Lysis of Human Erythrocytes Sensitized with Rhesus Alloantibodies," <i>British J. Haematology</i> , 1979, pp. 303-314, Vol. 42.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: March 18, 2010 <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		<b>Application Number</b> <b>Filing Date</b> <b>First Named Inventor</b> <b>Art Unit</b> <b>Examiner Name</b> <b>Attorney Docket Number</b>	10/576,794 05/24/2007 Abdessatar Chtourou 1656 Marsha M. Tsay 096183-0103
Sheet	6	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A59	WRIGHT et al., "Effect of Altered C <sub>H</sub> 2-associated Carbohydrate Structure on the Functional Properties and In Vivo Fate of Chimeric Mouse-Human Immunoglobulin G1, J. Exp. Med., Sept. 1994, pp. 1087-1096, Vol. 180, The Rockefeller University Press.	
	A60	WRIGHT et al., "Effect of C2-Associated Carbohydrate Structure on Ig Effector Function: Studies with Chimeric Mouse-Human IgG1 Antibodies in Glycosylation Mutants of Chinese Hamster Ovary Cells," J. of Immunol., 1998, pp. 3393-3402.	
	A61	WRIGHT et al., "Effect of glycosylation on antibody function: implications for genetic engineering," TIBTECH, Jan. 1997, pp. 26-32, Vol. 15.	
	A62	WRIGHT et al., "In vivo Trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure," Glycobiology, 2000, pp. 1347-1355, Vol. 10, No. 12.	
	A63	YANO et al., "Analysis of N-linked oligosaccharides in the Fc region of an antibody," Experiment Summary, 16 pages, 23 June to 28 July, 2009.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.